Followers | 144 |
Posts | 27707 |
Boards Moderated | 3 |
Alias Born | 02/07/2004 |
Thursday, October 19, 2017 1:04:58 PM
Oct. 19, 2017 12:59 PM ET|About: Pluristem Therapeutics...
(PSTI)|By: Douglas W. House, SA News Editor
The FDA designates Pluristem Therapeutics' (PSTI +2%) cell therapy PLX-R18 an Orphan Drug for the treatment of acute radiation syndrome.
PLX-R18 is designed to treat bone marrow that is unable to produce enough blood cells, a result of acute radiation exposure as well as other causes (e.g., chemo).
A Phase 1 study in patients with incomplete bone marrow recovery following hematopoietic cell transplant is currently is in process.
Among the benefits of Orphan Drug status in the U.S. is a seven-year period of market exclusivity for the indication, if approved.
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM